Background: Drug delivery across the blood-brain barrier (BBB) is a major limitation in the
treatment of central nervous system (CNS) disorders. Several approaches are being …

The prevalence of neurological/neurodegenerative diseases, such as Alzheimer's disease is
known to be increasing due to an aging population and is anticipated to further grow in the …

Drug delivery to the brain is an engaged research topic in the field of nanomedicine. The
passage of therapeutics into the brain parenchyma is more complicated than other body …

Due to the ability of the blood–brain barrier (BBB) to prevent the entry of drugs into the brain,
it is a challenge to treat central nervous system disorders pharmacologically. The …

Neurodegenerative diseases (NDD) result in irreversible loss of neurons. Dementia
develops when disease-induced neuronal loss becomes sufficient to impair both memory …

The blood–brain barrier (BBB) is meant to protect the brain from noxious agents; however, it
also significantly hinders the delivery of therapeutics to the brain. Several strategies have …

Neuronanomedicine is an emerging multidisciplinary field that aims to create innovative
nanotechnologies to treat major neurodegenerative disorders, such as Alzheimer's (AD) and …

This narrative review provides an overview of the current advances, challenges, and
opportunities in nanoparticle drug delivery for central nervous system (CNS) disorders. The …

The existence of blood–brain barrier (BBB) hampers the effective treatment of central
nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of …

Research in the field of nano-neuroscience is becoming a promising future direction given
the advantages presented by nanosystems for central nervous system (CNS) drug delivery …